Abstract:Vitiligo is an acquired chronic depigmenting disorder of the skin, with an estimated prevalence of 0.5% of the general population, characterized by the development of white macules resulting from a loss of epidermal melanocytes. The nomenclature has been revised after an extensive international work within the vitiligo global issues consensus conference, and vitiligo (formerly non-segmental vitiligo) is now a consensus umbrella term for all forms of generalized vitiligo. Two other subsets of vitiligo are segmental vitiligo and unclassified/undetermined vitiligo, which corresponds to focal disease and rare variants. A series of hypopigmented disorders may masquerade as vitiligo, and some of them need to be ruled out by specific procedures including a skin biopsy. Multiple mechanisms are involved in melanocyte disappearance, namely genetic predisposition, environmental triggers, metabolic abnormalities, impaired renewal, and altered inflammatory and immune responses. The auto-immune/inflammatory theory is the leading hypothesis because (1) vitiligo is often associated with autoimmune diseases; (2) most vitiligo susceptibility loci identified through genome-wide association studies encode immunomodulatory proteins; and (3) prominent immune cell infiltrates are found in the perilesional margin of actively depigmenting skin. However, other studies support melanocyte intrinsic abnormalities with poor adaptation of melanocytes to stressors leading to melanocyte instability in the basal layer, and release of danger signals important for the activation of the immune system. Recent progress in the understanding of immune pathomechanisms opens interesting perspectives for innovative treatment strategies. The proof of concept in humans of targeting of the IFNγ /Th1 pathway is much awaited. The interplay between oxidative stress and altered immune responses suggests that additional strategies aiming at limiting type I interferon activation pathway as background stabilizing therapies could be an interesting approach in vitiligo. This review covers classification and clinical aspects, pathophysiology with emphasis on immunopathogenesis, and promising therapeutic approaches.

Disorganisation of basement membrane zone architecture impairs melanocyte residence in vitiligo

Melanocyte-keratinocyte cross-talk in vitiligo

Vitiligo: Focus on Clinical Aspects, Immunopathogenesis, and Therapy

Intracellular virus sensor MDA5 exacerbates vitiligo by inducing the secretion of chemokines in keratinocytes under virus invasion

Multimodal Analyses of Stable Vitiligo Skin Identify Tissue Interactions That Control Disease Persistence

Endoplasmic Reticulum Dysfunction: An Emerging Mechanism of Vitiligo Pathogenesis

LB1599 Novel microenvironmental defects revealed by large scale transcriptome sequencing of lesional and nonlesional skin of vitiligo patients

Membrane Lipid Alterations as a Possible Basis for Melanocyte Degeneration in Vitiligo

Differential expression of extracellular matrix proteins in the lesional skin of vitiligo patients

Recent advances in understanding vitiligo

Membrane lipid defects are responsible for the generation of reactive oxygen species in peripheral blood mononuclear cells from vitiligo patients

Anatomically distinct fibroblast subsets determine skin autoimmune patterns

Vitiligo: A focus on pathogenesis and its therapeutic implications

The enigma and challenges of vitiligo pathophysiology and treatment

Vitiligo: An Autoimmune Skin Disease and its Immunomodulatory Therapeutic Intervention

[Ultrastructural Changes of Epidermal Calcium Gradient and Lipid Lamellar Membrane in Depigmented Skin Lesions of Vitiligo Patients].

Oxidative stress-induced hypermethylation and low expression of ANXA2R: novel insights into the dysfunction of melanocytes in vitiligo

Transcriptome Analysis Reveals Markers of Aberrantly Activated Innate Immunity in Vitiligo Lesional and Non-Lesional Skin

Vitiligo: An immune disease and its emerging mesenchymal stem cell therapy paradigm

An update on Vitiligo pathogenesis

Vitiligo: From Pathogenesis to Treatment